SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-23-007867
Filing Date
2023-03-24
Accepted
2023-03-24 17:19:08
Documents
13
Period of Report
2023-03-21
Items
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities

Document Format Files

Seq Description Document Type Size
1 FORM 8-K sabs20230324_8k.htm   iXBRL 8-K 30232
  Complete submission text file 0001437749-23-007867.txt   185851

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA sabs-20230321.xsd EX-101.SCH 4177
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE sabs-20230321_def.xml EX-101.DEF 14103
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE sabs-20230321_lab.xml EX-101.LAB 18628
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sabs-20230321_pre.xml EX-101.PRE 14125
7 EXTRACTED XBRL INSTANCE DOCUMENT sabs20230324_8k_htm.xml XML 4820
Mailing Address 2100 EAST 54TH STREET NORTH SIOUX FALLS SD 57104
Business Address 2100 EAST 54TH STREET NORTH SIOUX FALLS SD 57104 605-679-6980
SAB Biotherapeutics, Inc. (Filer) CIK: 0001833214 (see all company filings)

IRS No.: 853899721 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39871 | Film No.: 23760826
SIC: 2836 Biological Products, (No Diagnostic Substances)